Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

xpenses 19,155 13,820

Loss from operations (19,155) (13,820)

Interest and other income, net 1,080 1,057

Interest expense (291) (235)

Loss before noncontrolling

interest in Symphony Allegro, Inc. (18,366) (12,998)

Loss attributed to noncontrolling

interest in Symphony Allegro, Inc. 3,757 2,082

Net loss $(14,609) $(10,916)

Basic and diluted net loss per share $(0.47) $(0.46)

Shares used to compute

basic and diluted net loss per share 31,225 23,869

Alexza Pharmaceuticals, Inc.

(a development stage enterprise)

Condensed Consolidated Balance Sheets

(in thousands)

March 31, December 31,

2008 2007

Assets Unaudited (1)

Cash, cash equivalents and marketable

securities $75,716 69,391

Investments held by Symphony Allegro, Inc. 35,936 39,449

Other current assets 2,350 13,432

Total current assets 114,002 122,272

Property and equipment, net 25,999 26,156

Other non-current assets 694 697

Total assets 140,695 149,125

Liabilities and stockholders' equity

Current liabilities 15,741 16,180

Non-current liabilities
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics ... ICOTF), today reported results of its Oral Amphotericin ... HIV reservoirs.  The study, conducted by ImmuneCarta®, the ... in vitro effectiveness of Oral Amp B ... present in individuals despite intensive treatment with antiretroviral ...
(Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... As part of the,"SCIENCEsuisse" project, swissinfo.ch is presenting ... of disciplines. The focus is on,Switzerland,s high international ... SRG SSR idee suisse initiative, in collaboration with,the ... to give readers an insight into what,scientists are ...
... Strains A & B In,15 Minutes, Each year ... ill with "the,flu." Misdiagnosis of the flu is common ... this, overuse and unnecessary,use of antibiotics may be a ... This flu season, a new rapid flu test can ...
... Nov. 11 PointCross Inc., responding to ... Pharmaceuticals R&D industries, has released,a software catalyst ... business and technical solutions with extreme speed ... leading collaboration platform for,enterprise users. Larger global ...
Cached Biology Technology:25 Short Films About Top-Level Research on swissinfo.ch 2MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season 2PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time 2
(Date:8/19/2014)... scientists have identified a biomarker strongly associated with ... is resistant to many types of chemotherapy. The ... target for new therapeutics designed to treat this ... data taken from The Cancer Genome Atlas, molecular ... used powerful computational and bioinformatics techniques to detect ...
(Date:8/19/2014)... during warm phases and became extinct during cold phases, ... link between marine crocodilian diversity and the evolution of ... million years. , The research, led by Dr ... formerly from the University of Bristol, UK is published ... are ,cold-blooded, animals that mainly live in fresh waters ...
(Date:8/19/2014)... Anyone who has ever had a glass of fizzy ... the air. But in a finding with wide industrial ... push some particles down into the liquid as well. ... aerosol droplets, so we were surprised, and fascinated, to ... the same process injected tiny oil droplets into the ...
Breaking Biology News(10 mins):Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3Evolution of marine crocodilians constrained by ocean temperatures 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... psychological society in the world, will grant its ... to Psychology" to Dr Friederike Range of the ... Medicine, Vienna (Vetmeduni Vienna). The award is recognition ... will be made in August 2012 at a ...
... of rare, endemic species in the Central Andes remain ... climate change, according to a Duke University-led international study. ... particularly vulnerable to changes in the environment or climate. ... percent of the areas with high numbers of these ...
... New York, NY (January 26, 2012) Researchers at the ... variation that raises the risk of developing serious necrotic jaw ... of osteoclastic inhibitors. The discovery paves the way for a ... drugs. The study appears in the online version of the ...
Cached Biology News:Dancing with wolves -- prestigious award goes to a scientist at the Vetmeduni Vienna 280 percent of 'irreplaceable' habitats in Andes unprotected 2Study pinpoints genetic variation that raises a risk linked to bisphosphonates 2Study pinpoints genetic variation that raises a risk linked to bisphosphonates 3
... Virgin, optically clear polystyrene with frosted ... coordinates for cell counting. 100% integrity ... a new product number, created to ... showing no availability yet, please order ...
... surface is produced by a patented microwave ... giving more consistent, even cell attachment, increased ... attachment and growth uunder difficult conditions, including ... may provide a more ecominic alternative to ...
... system, 100-240 V, uses xMAP technology for ... proteins and peptides in one microplate well. ... to 100 color-coded bead sets, each of ... reactant (enzyme substrates, receptors, antigens, or antibodies) ...
...
Biology Products: